Statistik Asas
| LEI | 549300IFBVI51FN3NJ32 |
| CIK | 1477845 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Annovis Bio, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 ANNOVIS BIO, INC. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of regis |
|
| August 12, 2025 |
(Tables to follow) ANNOVIS BIO, INC. Balance Sheets Exhibit 99.1 Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results Malvern, Pa., August 12, 2025 – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates an |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2025 ANNOVIS BIO, INC. |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2025 ANNOVIS BIO, INC. |
|
| June 20, 2025 |
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance Exhibit 99.1 Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance Malvern, Pa., June 19, 2025 – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acce |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2025 ANNOVIS BIO, INC. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of regi |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2025 ANNOVIS BIO, INC. |
|
| May 13, 2025 |
(Tables to follow) ANNOVIS BIO, INC. Balance Sheets Exhibit 99.1 Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results Malvern, Pa., May 13, 2025 – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fir |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Sta |
|
| March 27, 2025 |
Annovis Bio, Inc. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE Exhibit 99.1 Annovis Bio, Inc. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE MALVERN, PA – March 27, 2025 – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that on March 26, 2025, it rec |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2025 ANNOVIS BIO, INC. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2025 ANNOVIS BIO, INC. |
|
| March 21, 2025 |
Exhibit 19.1 ANNOVIS BIO, INC. INSIDER TRADING POLICY (Adopted July 31, 2019) This Insider Trading Policy is designed to help persons understand the federal securities laws relating to insider trading and describes certain prohibited transactions in securities of Annovis Bio, Inc. (the “Company”) and, in certain cases, the securities of other companies. It also provides general guidelines with res |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39202 ANNOVIS BIO, INC. (Exact name of registran |
|
| March 21, 2025 |
Description of Registrant’s Securities. Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation (the “Amended |
|
| March 21, 2025 |
(Tables to follow) ANNOVIS BIO, INC. Balance Sheets Exhibit 99.1 Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results Malvern, Pa., Mar. 21, 2025 – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corpora |
|
| February 5, 2025 |
Exhibit 1.1 UNDERWRITING AGREEMENT between Annovis Bio, Inc. and ThinkEquitY LLC as Representative of the Several Underwriters ANNOVIS BIO, INC. UNDERWRITING AGREEMENT New York, New York February 3, 2025 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: The undersigned, Annovi |
|
| February 5, 2025 |
Exhibit 4.2 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agreement”) dated as of February 4, 2025 (the “Issuance Date”) between Annovis Bio., Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (the “Purchase Agreement”), |
|
| February 5, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 ANNOVIS BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39202 26-2540421 (State or other jurisdiction of incorporation) (Commission File |
|
| February 5, 2025 |
Exhibit 99.1 Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease MALVERN, Pa., Feb. 5, 2025 – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announ |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2025 ANNOVIS BIO, INC. |
|
| February 5, 2025 |
Annovis Bio, Inc. Announces Proposed Public Offering Exhibit 99.1 Annovis Bio, Inc. Announces Proposed Public Offering MALVERN, PA – January 31, 2025 – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it intends to offer to sell common stock and |
|
| February 5, 2025 |
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering Exhibit 99.2 Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering MALVERN, PA – February 3, 2025 – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the pricing of an underwritten publi |
|
| February 5, 2025 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ANNOVIS BIO, INC. Warrant Shares: Issue Date: February 4, 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, . or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February 4, 2025 (the “Initial Exer |
|
| February 5, 2025 |
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering Exhibit 99.3 Annovis Bio, Inc. Announces Closing of $21 Million Public Offering MALVERN, PA – February 4, 2025 – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announ |
|
| February 4, 2025 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-276814 PROSPECTUS SUPPLEMENT (To the Prospectus dated February 12, 2024) 5,250,000 Units, Each Consisting of One Share of Common Stock and One Warrant to Purchase Common Stock 5,250,000 Shares Underlying Warrants to Purchase Common Stock Annovis Bio, Inc. This is a firm commitment public offering of the securities |
|
| February 3, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276814 The information contained in this preliminary prospectus supplement is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus supplement and the accompanying prospectus are not an off |
|
| December 11, 2024 |
Exhibit 1.1 Annovis Bio Inc. $50,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT December 11, 2024 Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, New York 10004 Ladies and Gentlemen: Annovis Bio Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc., as follows: 1. Issuance and Sale o |
|
| December 11, 2024 |
Exhibit 99.1 December 11, 2024 Development path to NDA for • Alzheimer’s disease • Parkinson’s disease Investor Update 2 FORWARD - LOOKING STATEMENTS Forward Looking Statements and Other Important Cautions - This presentation contains "forward - looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, a |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 ANNOVIS BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39202 26-2540421 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 11, 2024 |
ANNOVIS BIO, INC. $50,000,000 Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-276814 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2024) ANNOVIS BIO, INC. $50,000,000 Common Stock We have entered into an Equity Distribution Agreement, or the Distribution Agreement, dated as of December 11, 2024, with Oppenheimer & Co. Inc., or Oppenheimer, relating to the sale of shares of our com |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2024 ANNOVIS BIO, INC. |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 4, 2024 ANNOVIS BIO, INC. |
|
| November 12, 2024 |
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update EX-99.1 2 tm2427939d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Annovis Bio Reports Third Quarter Financial Results and Provides Business Update MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) – via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinso |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 ANNOVIS BIO, INC. |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2024 ANNOVIS BIO, INC. |
|
| October 15, 2024 |
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs Exhibit 99.1 FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs MALVERN, Pa., October 15, 2024 (GLOBE NEWSWIRE) – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced tod |
|
| September 30, 2024 |
Exhibit 99.1 Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra MALVERN, Pa., September 30, 2024 (GLOBE NEWSWIRE) – via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s di |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2024 ANNOVIS BIO, INC. |
|
| August 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2024 ANNOVIS BIO, INC. |
|
| August 15, 2024 |
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update Exhibit 99.1 Annovis Bio Reports Second Quarter Financial Results and Provides Business Update MALVERN, Pa., August 15, 2024 (GLOBE NEWSWIRE) - via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced financial |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of regis |
|
| August 6, 2024 |
Exhibit 99.1 Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist MALVERN, Pa., August 6, 2024 (GLOBE NEWSWIRE) - via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced n |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 ANNOVIS BIO, INC. |
|
| July 16, 2024 |
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap Exhibit 99.1 Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) - via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced tod |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2024 ANNOVIS BIO, INC. |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2024 ANNOVIS BIO, INC. |
|
| July 2, 2024 |
Exhibit 99.1 Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2024 ANNOVIS BIO, INC. |
|
| June 21, 2024 |
As filed with the Securities and Exchange Commission on June 21, 2024 As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| June 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Annovis Bio, Inc. |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (date of earliest event reported): June 13, 2024 ANNOVIS BIO, INC. (Exact name of registrant as specified in charter) Delaware 001-39202 26-2540421 (State of Incorporation) (Commission File No.) (IRS Employer Identificati |
|
| June 11, 2024 |
Investor Webcast 6/11/2024 NYSE: ANVS - People Focused, Purpose Driven, Passion Powered - Exhibit 99.2 Investor Webcast 6/11/2024 NYSE: ANVS - People Focused, Purpose Driven, Passion Powered - FORWARD - LOOKING STATEMENTS Forward Looking Statements and Other Important Cautions - This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . These forward - looking statements relate to all information other than histo |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2024 ANNOVIS BIO, INC. |
|
| June 11, 2024 |
Exhibit 99.1 Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients Join Our Investor Call for In-Depth Findings Discussion MALVERN, Pa., June,11 2024 (GLOBE NEWSWIRE) - Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2024 ANNOVIS BIO, INC. |
|
| June 5, 2024 |
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast Exhibit 99.1 Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast MALVERN, Pa. June 5, 2024 - Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss re |
|
| May 21, 2024 |
Annovis Announces New Publication in a Peer-Reviewed Journal Exhibit 99.1 Annovis Announces New Publication in a Peer-Reviewed Journal MALVERN, Pa. - May 21, 2024 - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across diffe |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 ANNOVIS BIO, INC. |
|
| May 13, 2024 |
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results Exhibit 99.1 Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results MALVERN, Pa. - May 13, 2024 - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Update |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 ANNOVIS BIO, INC. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of regi |
|
| May 9, 2024 |
ANNOVIS ANNOUNCES UNBLINDING OF THE BUNTANETAP PHASE III DATA IN PARKINSON’S DISEASE Exhibit 99.1 ANNOVIS ANNOUNCES UNBLINDING OF THE BUNTANETAP PHASE III DATA IN PARKINSON’S DISEASE MALVERN, Pa. - May 9, 2024 - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with earl |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 ANNOVIS BIO, INC. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 6, 2024 |
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders Exhibit 99.1 Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders MALVERN, Pa. - May 6, 2024 - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase I |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2024 ANNOVIS BIO, INC. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2024 ANNOVIS BIO, INC. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 ANNOVIS BIO, INC. |
|
| May 1, 2024 |
Annovis Bio, Inc. Up to 2,051,428 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-276814 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2024) Annovis Bio, Inc. Up to 2,051,428 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to 2,051,428 shares of our common stock that we may sell to Keystone Capital Partners, LLC (“Keystone”) from time to time, p |
|
| May 1, 2024 |
Exhibit 10.1 SEPARATION Agreement AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE (the “Agreement”) is entered into by and between Annovis Bio, Inc. (the “Company”) and Henry Hagopian, III (“Executive”). WHEREAS, the Company and Executive are mutually terminating Executive’s employment with the Company effective April 30, 2024 (the “Separation Date”); and WHEREAS, Executive and t |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Def |
|
| April 26, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 25, 2024, is by and between Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and Annovis Bio, Inc., a Delaware corporation (the “Company”). RECITALS A. The Company and the Investor have entered into that certain Common Stock Purchase A |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2024 ANNOVIS BIO, INC. |
|
| April 26, 2024 |
Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT Dated as of April 25, 2024 by and among ANNOVIS BIO, INC., and KEYSTONE CAPITAL PARTNERS, LLC Table of Contents Page Article I PURCHASE AND SALE OF COMMON STOCK 2 Section 1.1. Purchase and Sale of Stock 2 Section 1.2. Closing Date; Settlement Dates 2 Section 1.3. Initial Public Announcements and Required Filings 3 Article II PURCHASE TERMS 3 Section 2.1 |
|
| April 3, 2024 |
Exhibit 99.1 ANNOVIS BIO PROVIDES CORPORATE UPDATES AND REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Tue, 02 Apr 2024 MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported f |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2024 ANNOVIS BIO, INC. |
|
| March 29, 2024 |
Exhibit 4.4 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation (the “Amended |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39202 Annovis Bio |
|
| March 29, 2024 |
Exhibit 97.1 Clawback Policy This Clawback Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Annovis Bio, Inc. (the “Company”) in light of the effective date of October 2, 2023 (the “Effective Date”) of the listing requirements adopted by the New York Stock Exchange LLC (“NYSE”) in the form of Section 303A.14 Erroneously Awarded Compensation (“Section 303A.14”) tha |
|
| March 29, 2024 |
NONQUALIFIED STOCK OPTION AGREEMENT Exhibit 10.6 NONQUALIFIED STOCK OPTION AGREEMENT THIS AGREEMENT, effective as of , 20, is made by and between Annovis Bio, Inc. (the “Company”), a Delaware corporation, and [] (the “Employee”), an employee of the Company. Recitals: WHEREAS, the Company has established the Annovis Bio, Inc. 2019 Equity Incentive Plan, as amended (the “Plan”), the terms of which are hereby incorporated by reference |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 ANNOVIS BIO, INC. |
|
| March 22, 2024 |
316,455 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-276814 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2024) 316,455 Shares of Common Stock We are offering 316,455 shares (the “Shares”) of our common stock, $0.0001 par value per share (the “Common Stock”) in a registered direct offering to an institutional investor (the “Investor”) pursuant to this prospectus supplement and the accom |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2024 ANNOVIS BIO, INC. |
|
| March 21, 2024 |
Securities Purchase Agreement, dated March 21, 2024 Exhibit 10.2 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 21, 2024, is by and among Annovis Bio, Inc., a Delaware corporation with headquarters located at 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” an |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 19, 2024 ANNOVIS BIO, INC. |
|
| March 20, 2024 |
Exhibit 99.1 ANNOVIS BIO PROVIDES DATA ANNOUNCEMENT UPDATE FOR THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER’S DISEASE MALVERN, Pa.—March 20, 2024 - Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2024 ANNOVIS BIO, INC. |
|
| March 19, 2024 |
114,911 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-276814 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2023) 114,911 Shares of Common Stock We are offering 114,911 shares (the “Shares”) of our common stock, $0.0001 par value per share (the “Common Stock”) in a registered direct offering to an institutional investor (the “Investor”) pursuant to this prospectus supp |
|
| March 19, 2024 |
114,911 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-276814 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2023) 114,911 Shares of Common Stock We are offering 114,911 shares (the “Shares”) of our common stock, $0.0001 par value per share (the “Common Stock”) in a registered direct offering to an institutional investor (the “Investor”) pursuant to this prospectus supp |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2024 ANNOVIS BIO, INC. |
|
| March 15, 2024 |
Securities Purchase Agreement, dated March 15, 2024 Exhibit 10.2 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 15, 2024, is by and among Annovis Bio, Inc., a Delaware corporation with headquarters located at 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” an |
|
| February 12, 2024 |
As filed with the Securities and Exchange Commission on February 12, 2024 As filed with the Securities and Exchange Commission on February 12, 2024 Registration No. |
|
| February 9, 2024 |
Annovis Bio, Inc. 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 Tel: (484) 875-3192 Annovis Bio, Inc. 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 Tel: (484) 875-3192 February 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Annovis Bio, Inc. Registration Statement on Form S-3 File No. 333-276814 Dear Mr. Crawford: Pursuant to Rule 461 under the Securities Act of |
|
| February 1, 2024 |
Exhibit 4.5 ANNOVIS BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities i TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definition of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.03 Den |
|
| February 1, 2024 |
As filed with the Securities and Exchange Commission on February 1, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 1, 2024 Registration No. |
|
| February 1, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Annovis Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registrat |
|
| November 28, 2023 |
ANVS / Annovis Bio Inc / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Annovis Bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03615A108 (CUSIP Number) November 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 8, 2023 |
ANVS / Annovis Bio Inc / HIRSCHMAN ORIN Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Annovis Bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03615A108 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of |
|
| November 1, 2023 |
Exhibit 10.1 Execution Version ANNOVIS BIO, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [] Number of Warrant Shares: [] Date of Issuance: November 2, 2023 (“Issuance Date”) Annovis Bio, Inc., a Delaware corporation (the “Company”), certifies that, for good and valuable consideration, the receipt and sufficiency of which are acknowledged, , the registered holder hereof or its permitted assig |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2023 ANNOVIS BIO, INC. |
|
| November 1, 2023 |
Annovis Bio Announces Launch of Proposed Public Offering Exhibit 99.1 Annovis Bio Announces Launch of Proposed Public Offering BERWYN, PENNSYLVANIA, October 30, 2023 /BUSINESS WIRE/ - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced a proposed underwritten public offering i |
|
| November 1, 2023 |
Underwriting Agreement, dated October 31, 2023, between Annovis Bio, Inc. and Canaccord Genuity LLC. Exhibit 1.1 ANNOVIS BIO, INC. 1,250,000 Shares of Common Stock Warrants to Purchase 1,250,000 Shares of Common Stock UNDERWRITING AGREEMENT October 31, 2023 Canaccord Genuity LLC As Representative of the several Underwriters listed in Schedule 1 hereto 99 High Street, 11th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Annovis Bio, Inc., a Delaware corporation (the “Company”), proposes to |
|
| November 1, 2023 |
1,250,000 Shares of Common Stock Warrants to Purchase 1,250,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252625 PROSPECTUS SUPPLEMENT (to Prospectus dated February 11, 2021) 1,250,000 Shares of Common Stock Warrants to Purchase 1,250,000 Shares of Common Stock We are offering 1,250,000 shares of our common stock (the “Shares”) and warrants to purchase up to 1,250,000 shares of our common stock at an exercise price of $9.00 per whole share of commo |
|
| November 1, 2023 |
Annovis Bio Announces Pricing of $7.5 Million Public Offering Exhibit 99.2 Annovis Bio Announces Pricing of $7.5 Million Public Offering BERWYN, PENNSYLVANIA, October 31, 2023 /BUSINESS WIRE/ - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced the pricing of an underwritten publi |
|
| October 30, 2023 |
Exhibit 99.1 ANNOVIS BIO RECEIVES POSITIVE RECOMMENDATION TO CONTINUE PHASE 2/3 TRIAL OF BUNTANETAP FOR alzheimer’S DISEASE PATIENTS FROM THE INDEPENDENT DATA AND SAFETY MONITORING BOARD (DSMB) BERWYN, PENNSYLVANIA - October 30, 2023 (BUSINESS WIRE)- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 tri |
|
| October 30, 2023 |
Subject to completion, dated October 30, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-252625 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and w |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2023 ANNOVIS BIO, INC. |
|
| October 13, 2023 |
Exhibit 99.1 ANNOVIS BIO ANNOUNCES POSITIVE interim INDEPENDENT analysis For STATISTICAL POWER IN its Alzheimer’s study October 12, 2023 Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients. BERWYN, Pa., October 12, 2023 /PRNewswire/ |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2023 ANNOVIS BIO, INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of regis |
|
| June 16, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANNOVIS BIO, INC. Annovis Bio, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST, The name of the Corporation is Annovis Bio, Inc. The original Certificate of Incorporation of A |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 ANNOVIS BIO, INC. |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 30, 2023 |
Letter dated May 30, 2023 from WithumSmith+Brown PC to the U.S. Securities and Exchange Commission Exhibit 16.1 May 30, 2023 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read Annovis Bio, Inc. statements included under Item 4.01 of its Form 8-K dated May 30, 2023. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on May 25, 2023. We are not in a p |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 ANNOVIS BIO, INC. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of regi |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2023 ANNOVIS BIO, INC. |
|
| April 3, 2023 |
Exhibit 99.1 ANNOVIS BIO ANNOUNCES FOURTH QUARTER and full year 2022 financial RESULTS AND PROVIDES CORPORATE UPDATE BERWYN, Penn., April 3, 2023 /PRNewswire/ - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, has announced fourth quarter and full year financial results for the period ended December 31, 2022, |
|
| April 3, 2023 |
Exhibit 1.1 EXECUTION VERSION ANNOVIS BIO, INC. Common Stock ($0.0001 par value) ATM EQUITY OFFERINGSM SALES AGREEMENT March 31, 2023 BofA Securities, Inc. ThinkEquity LLC c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o ThinkEquity LLC 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: Annovis Bio, Inc., a Delaware corporation (the “Company”), propose |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2023 ANNOVIS BIO, INC. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 ANNOVIS BIO, INC. |
|
| March 31, 2023 |
Exhibit 10.6 NONQUALIFIED STOCK OPTION AGREEMENT THIS AGREEMENT, effective as of , 20, is made by and between Annovis Bio, Inc. (the “Company”), a Delaware corporation, and [] (the “Employee”), an employee of the Company. Recitals: WHEREAS, the Company has established the Annovis Bio, Inc. 2019 Equity Incentive Plan, as amended (the “Plan”), the terms of which are hereby incorporated by reference |
|
| March 31, 2023 |
Exhibit 107 The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offering of equity securities. The maximum aggregate offering price is $50,000,000. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 ANNOVIS BIO, INC. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39202 Annovis Bio |
|
| March 31, 2023 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252625 P R O S P E C T U S S U P P L E M E N T Up to $50,000,000 Common Stock We have entered into a sales agreement with BofA Securities, Inc. and ThinkEquity LLC, as Sales Agents, relating to the sale of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreemen |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 ANNOVIS BIO, INC. |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2023 ANNOVIS BIO, INC. |
|
| February 13, 2023 |
Exhibit 99.1 Attacks Neurodegeneration, Alzheimer’s and Parkinson’s Diseases by Improving the Information Highway of the Nerve Cell February 2023 Symbol: ANVS (NYSE) - People Focused, Purpose Driven, Passion Powered - FORWARD-LOOKING STATEMENTS Forward Looking Statements and Other Important Cautions - This presentation contains forward-looking statements within the meaning of the Private Securitie |
|
| January 6, 2023 |
Exhibit 99.1 Attacks Neurodegeneration, Alzheimer?s and Parkinson?s Diseases by Improving the Information Highway of the Nerve Cell January 2023 Symbol: ANVS (NYSE) - People Focused, Purpose Driven, Passion Powered - FORWARD - LOOKING STATEMENTS Forward Looking Statements and Other Important Cautions - This presentation contains forward - looking statements within the meaning of the Private Securi |
|
| January 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2023 ANNOVIS BIO, INC. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| September 12, 2022 |
Exhibit 10.1 SePARATION Agreement AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE (the ?Agreement?) is entered into by and between Annovis Bio, Inc. (the ?Company?) and Jeffrey B. McGroarty (?Executive?). WHEREAS, the Company is terminating Executive?s employment with the Company without cause effective September 9, 2022 (the ?Separation Date?), pursuant to Section 4(c) of Execut |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2022 ANNOVIS BIO, INC. |
|
| August 30, 2022 |
Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer Exhibit 99.1 Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer BERWYN, PA., Aug. 29, 2022 /PRNewswire/ - Annovis Bio, Inc. (NYSE: ANVS) (?Annovis? or the ?Company?), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately. Mr. Hagopian comes to Annovis with 30 ye |
|
| August 30, 2022 |
Exhibit 10.1 ? ? Mr.?Henry Hagopian,?III 56 Robert Road Stow, MA ?01775 ? Re:????????????Employment Offer ? Dear Henry: ? On behalf of Annovis Bio,?Inc. (the ?Company?),?I am pleased to offer you employment as Chief Financial of the Company, reporting to the Company?s Chief Executive Officer or her designee. The purpose of this letter is to set forth the terms of the offer. ? 1.????????????Positio |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2022 ANNOVIS BIO, INC. |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 ANNOVIS BIO, INC. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2022 |
Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update Exhibit 99.1 Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update Berwyn, Pennsylvania?August 8, 2022 - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments. Maria L |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2022 ANNOVIS BIO, INC. |
|
| May 4, 2022 |
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update Exhibit 99.1 Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update Berwyn, Pennsylvania ? May 4, 2022 ? Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update. Maria L. Macc |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 ANNOVIS BIO, INC. |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39202 ANNOVIS BIO, INC. NYSE American (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 1055 Westlakes Drive, |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ANNOVIS BIO, INC. (Exact name of registrant as specified in its charter) Delaware 26-2540421 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 1 |
|
| November 15, 2021 |
Exhibit 99.1 Annovis Bio Announces Transfer of Listing to the New York Stock Exchange Trading to begin November 18, 2021 with current ticker ?ANVS? BERWYN, PA., November 15, 2021 - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today ann |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2021 ANNOVIS BIO, INC. |
|
| November 12, 2021 |
Exhibit 99.1 Annovis Bio Presented at the 14th Clinical Trials on Alzheimer?s Disease Conference With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a study BERWYN, PA., November 12, 2021 - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), |
|
| November 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2021 ANNOVIS BIO, INC. |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 5, 2021 |
New Parkinson’s Efficacy Data Symbol: ANVS (NYSE American) October 5, 2021 Exhibit 99.2 New Parkinson?s Efficacy Data Symbol: ANVS (NYSE American) October 5, 2021 FORWARD - LOOKING STATEMENTS Statements in this presentation contain ?forward - looking statements? that are subject to substantial risks and uncertainties. Forward - looking statements contained in this presentation may be identified by the use of words such as ?anticipate,? ?expect,? ?believe,? ?will,? ?may,? |
|
| October 5, 2021 |
Exhibit 99.1 Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson?s Disease Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development Investor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ET BERWYN, PA., October 5, 2021 - Annovis Bio |
|
| October 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 5, 2021 ANNOVIS BIO, INC. |
|
| August 11, 2021 |
Frequently Asked Questions Annovis Bio Phase 2a Data Results Exhibit 99.1 Frequently Asked Questions Annovis Bio Phase 2a Data Results 1. What interim results from the Phase 2a study of ANVS401 were recently announced by Annovis Bio? Why did some people believe the company?s recent interim data readout was negative? Answer: On July 28, we announced interim results among both Alzheimer?s disease (AD) and Parkinson?s disease (PD) patients from Phase 2a clinic |
|
| August 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2021 ANNOVIS BIO, INC. |
|
| July 29, 2021 |
AAIC Panel July 28, 2021 Symbol: ANVS (NYSE American) Exhibit 99.1 AAIC Panel July 28, 2021 Symbol: ANVS (NYSE American) NEUROTOXIC PROTEINS IMPAIR AXONAL TRANSPORT AND CAUSE A TOXIC CASCADE Posiphen IMPROVES AXONAL TRANSPORT AND IMPEDES THE TOXIC CASCADE IMPAIRED AXONAL TRANSPORT SLOWER SYNAPTIC TRANSMISSION INFLAMMATION DEATH OF NERVE CELLS LOSS OF COGNITIVE AND MOTOR FUNCTION IMPROVED AXONAL TRANSPORT INCREASED SYNAPTIC TRANSMISSION NO INFLAMMATIO |
|
| July 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2021 ANNOVIS BIO, INC. |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 3, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2021 ANNOVIS BIO, INC. |
|
| May 24, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2021 ANNOVIS BIO, INC. |
|
| May 24, 2021 |
Exhibit 1.1 UNDERWRITING AGREEMENT between ANNOVIS BIO, INC. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters ANNOVIS BIO, INC. UNDERWRITING AGREEMENT New York, New York May 23, 2021 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Str |
|
| May 24, 2021 |
Annovis Bio, Inc. Announces Pricing of Public Offering Exhibit 99.2 Annovis Bio, Inc. Announces Pricing of Public Offering Berwyn, Pennsylvania, May 23, 2021 ? Annovis Bio, Inc. (NYSE American: ANVS), (?Annovis? or the ?Company?), a clinical-stage drug platform company addressing Alzheimer?s disease (AD), Parkinson?s disease (PD) and other neurodegenerative diseases, today announced the pricing of its underwritten public offering of 1,000,000 shares o |
|
| May 24, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-252625 PROSPECTUS SUPPLEMENT (to Prospectus dated February 1, 2021) 1,000,000 Shares Common Stock Annovis Bio, Inc. We are offering 1,000,000 shares of our common stock. The purchase price for each share is $50.00. Our common stock is listed on the NYSE American under the symbol ?ANVS.? On May 20, 2021, the last reported sale price of our commo |
|
| May 24, 2021 |
Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock Berwyn, PA ? May 21, 2021 ? Annovis Bio, Inc. (NASDAQ: ANVS) (?Annovis? or the ?Company?) a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that it intends to offer to sell shares of its common stock in an underwr |
|
| May 21, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-252625 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and w |
|
| May 21, 2021 |
Filed Pursuant to Rule 433 Registration No. 333-252625 Issuer Free Writing Prospectus dated May 21, 2021 Relating to Preliminary Prospectus Supplement dated May 21, 2021 Attacks Alzheimer?s Disease and Neurodegeneration by Improving the Information Highway of the Nerve Cell Axonal Transport May 2021 Symbol: ANVS (NYSE American) FORWARD - LOOKING STATEMENTS Statements in this presentation contain ? |
|
| May 6, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 6, 2021 |
Exhibit 10.1 ? CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Wilmington PharmaTech Company LLC ? 229A Lake Drive Newark, DE 19702, USA Phone: (302) 737-9916 Fax: (302) 261-7000 Web: www.WilmingtonPharmaTech.com ? ? |
|
| April 19, 2021 |
Our Definitive Proxy Statement filed with the SEC on April 19, 2021; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission |
|
| April 15, 2021 |
Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman Exhibit 99.1 Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman BERWYN, PA. ? April 15, 2021 ? Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer?s disease (AD), Parkinson?s disease (PD) and other neurodegenerative diseases, today announced the appointment of Reid S. McCarthy to its Board of Directors and to the role |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2021 ANNOVIS BIO, INC. |
|
| March 23, 2021 |
Exhibit 99.1 Attacks Alzheimer’s Disease and Neurodegeneration by Improving the Information Highway of the Nerve Cell Axonal Transport March 2021 Symbol: ANVS (NYSE American) FORWARD - LOOKING STATEMENTS Statements in this presentation contain “forward - looking statements” that are subject to substantial risks and uncertainties. Forward - looking statements contained in this presentation may be i |
|
| March 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2021 ANNOVIS BIO, INC. |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2021 ANNOVIS BIO, INC. |
|
| March 3, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 9, 2021 |
ANNOVIS BIO, INC. 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 February 9, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Annovis Bio, Inc. Registration Statement on Form S-3 Filed February 1, 2021 File No. 333-252625 Dear Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, a |
|
| February 1, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 1, 2021 Registration No. |
|
| January 28, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 Annovis Bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03615A108 (CUSIP Number) January 21, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| November 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of |
|
| July 29, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of regis |
|
| July 21, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Annovis Bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03615A108 (CUSIP Number) July 10, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ Rul |
|
| July 10, 2020 |
03615A108 / ANNOVIS BIO INC / HIRSCHMAN ORIN - AMENDED SC13G - NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Annovis Bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03615A108 (CUSIP Number) July 7, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| July 6, 2020 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Maria Maccecchini and Jeffrey McGroarty, and any of their substitutes, signing singly, as the undersigned’s true and lawful attorney-in-fact to: 1. |
|
| June 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2020 ANNOVIS BIO, INC. |
|
| June 9, 2020 |
Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit Exhibit 99.1 Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit BERWYN, PA. – June 9, 2020 – Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced that CEO Maria Maccecchini, Ph.D. and CFO Jeff McGroarty, MBA, CPA, will give a virtual corp |
|
| June 9, 2020 |
Exhibit 99.2 Attacks Alzheimer’s Disease and Neurodegeneration by Improving the Information Highway of the Nerve Cell Axonal Transport June 2020 Symbol: ANVS (NYSE American) FORWARD - LOOKING STATEMENTS Statements in this presentation contain “forward - looking statements” that are subject to substantial risks and uncertainties. Forward - looking statements contained in this presentation may be id |
|
| June 5, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2020 ANNOVIS BIO, INC. |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of registrant as specifie |
|
| April 24, 2020 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission |
|
| April 20, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) ANNOVIS BIO, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03615A108 (CUSIP Number) Maria Maccecchini, Ph.D. President and Chief Executive Officer Annovis Bio, Inc. 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 (610) 727-3913 (N |
|
| April 20, 2020 |
EX-1 2 a20-163751ex1.htm EX-1 Exhibit 1 Lock-Up Agreement December 17, 2019 ThinkEquity A Division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 As Representative of the several Underwriters named on Schedule 1 to the Underwriting Agreement referenced below Ladies and Gentlemen: The undersigned understands that ThinkEquity, a Division of Fordham Financial Man |
|
| April 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2020 ANNOVIS BIO, INC. |
|
| March 25, 2020 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT effective as of March 24, 2020 (this ?Agreement?) between Annovis Bio, Inc. (the ?Company?), a Delaware corporation, and Maria L. Maccecchini (the ?Executive?). Background: The parties desire to enter into this Agreement to provide for the employment of the Executive by the Company from and after the Commencement Da |
|
| March 25, 2020 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation (the ?Amended |
|
| March 25, 2020 |
Exhibit 10.9 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT effective as of March 24, 2020 (this ?Agreement?) between Annovis Bio, Inc. (the ?Company?), a Delaware corporation, and Jeffrey B. McGroarty (the ?Executive?). Background: The parties desire to enter into this Agreement to provide for the employment of the Executive by the Company and for certain other matters in connection with such employme |
|
| March 25, 2020 |
Exhibit 4.2 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE DATE OF THE UNDERWRIT |
|
| March 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39202 Annovis Bio, Inc. (Exact name |
|
| February 14, 2020 |
As filed with the Securities and Exchange Commission on February 14, 2020 Registration No. |
|
| February 6, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ANNOVIS BIO, INC. (a Delaware corporation) Effective as of January 31, 2020 TABLE OF CONTENTS Page Article 1 OFFICES Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 Article 2 CORPORATE SEAL Section 2.1 Corporate Seal 1 Article 3 STOCKHOLDERS? MEETINGS Section 3.1 Place of Meetings 1 Section 3.2 Annual Meetings 1 Section 3.3 Special Meetings 5 |
|
| February 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2020 ANNOVIS BIO, INC. |
|
| February 6, 2020 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANNOVIS BIO, INC. The name of the Corporation is Annovis Bio, Inc. (the ?Corporation?). The Corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware (the ?DGCL?) on April 29, 2008 (the ?Original Certificate of Incorporation?). The Original Certificate of Incorporation was amended on Dec |
|
| January 30, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Table of Contents Filed pursuant to Rule 424(b)(4) Registration Nos. |
|
| January 30, 2020 |
Passive Investment - ACQUISITION OF BENEFICIAL OWNERSHIP SC 13G 1 anvs-sc13g012920.htm ACQUISITION OF BENEFICIAL OWNERSHIP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Annovis Bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03615A108 (CUSIP Number) January 29, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 29, 2020 |
As filed with the Securities and Exchange Commission on January 29, 2020 Registration No. |
|
| January 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ANNOVIS BIO, INC. (Exact name of registrant as specified in its charter) Delaware 26-2540421 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 1 |
|
| January 24, 2020 |
January 24, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 24, 2020 |
ANNOVIS BIO, INC. 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 January 24, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Healthcare & Insurance Re: Annovis Bio Registration Statement on Form S-1 Filed July 2, 2019 File No. 333-232529 Ladies and Gentlemen: Pursuant to Rule 461 promulgated und |
|
| January 24, 2020 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT between ANNOVIS BIO, INC. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters ANNOVIS BIO, INC. UNDERWRITING AGREEMENT New York, New York January [?], 2020 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 17 Stat |
|
| January 24, 2020 |
QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on January 24, 2020 Registration No. |
|
| January 21, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on January 21, 2020 Registration No. |
|
| January 21, 2020 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT between ANNOVIS BIO, INC. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters ANNOVIS BIO, INC. UNDERWRITING AGREEMENT New York, New York January [?], 2020 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 17 Stat |
|
| December 10, 2019 |
Issuer Free Writing Prospectus Filer: Annovis Bio, Inc. Filed Pursuant to Rule 433 Registration No. 333-232529 December 10, 2019 Attacks Alzheimer?s Disease and Neurodegeneration by Improving the Information Highway of the Nerve Axonal Transport Cell Proposed Symbol: ANVS (NYSE American) D e c e m b e r 2 0 1 9 DISCLAIMER We have filed a registration statement (including a preliminary prospectus) |
|
| November 19, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Table of Contents As filed with the Securities and Exchange Commission on November 19, 2019 Registration No. |
|
| September 20, 2019 |
Exhibit 4.1 AB ANNOVIS BIO, INC. SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 03615A 10 8 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT IS THE RECORD HOLDER OF FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF ANNOVIS BIO, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of the Cert |
|
| September 20, 2019 |
NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO BOSTON HOUSTON LOS ANGELES HANOI HO CHI MINH CITY ATLANTA FIRM and AFFILIATE OFFICES www. |
|
| September 20, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Table of Contents As filed with the Securities and Exchange Commission on September 20, 2019 Registration No. |
|
| August 28, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Table of Contents As filed with the Securities and Exchange Commission on August 27, 2019 Registration No. |
|
| August 27, 2019 |
NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO BOSTON HOUSTON LOS ANGELES HANOI HO CHI MINH CITY ATLANTA FIRM and AFFILIATE OFFICES www. |
|
| August 8, 2019 |
Exhibit 10.8 FORM OF ANNOVIS BIO, INC. 2019 EQUITY INCENTIVE PLAN The purpose of the Annovis Bio, Inc. 2019 Equity Incentive Plan is to provide (i) designated employees of Annovis Bio, Inc. (the ?Company?) and its parents and subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its parents or subsidiaries and (iii) non-employee members of the Board of Directo |
|
| August 8, 2019 |
Exhibit 3.4 FORM OF AMENDED AND RESTATED BY-LAWS OF ANNOVIS BIO, INC. (a Delaware corporation) Effective as of , 2019 TABLE OF CONTENTS Page ARTICLE 1 OFFICES Registered Office 1 Other Offices 1 ARTICLE 2 CORPORATE SEAL Section 2.1 Corporate Seal 1 ARTICLE 3 STOCKHOLDERS? MEETINGS Section 3.1 Place of Meetings 1 Annual Meetings 1 Special Meetings 5 Notice of Meetings 6 Quorum 6 Adjournment and Not |
|
| August 8, 2019 |
Exhibit 3.1 CERTIFICATE OF INCORPORATION OF QR PHARMA, INC. The undersigned, for the purpose of forming a corporation pursuant to the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: ARTICLE I The name of the corporation is QR Pharma, Inc. (the ?Corporation?). ARTICLE II The address of the Corporation?s registered office in the State |
|
| August 8, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Table of Contents As filed with the Securities and Exchange Commission on August 8, 2019 Registration No. |
|
| August 8, 2019 |
NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO BOSTON HOUSTON LOS ANGELES HANOI HO CHI MINH CITY ATLANTA FIRM and AFFILIATE OFFICES www. |
|
| August 8, 2019 |
Exhibit 3.2 FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANNOVIS BIO, INC. The name of the Corporation is Annovis Bio, Inc. (the ?Corporation?). The Corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware (the ?DGCL?) on April 29, 2008 (the ?Original Certificate of Incorporation?). The Original Certificate of Incorporation was amende |
|
| August 8, 2019 |
Exhibit 10.5 QR PHARMA, INC. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) dated as of December 19, 2014 among QR Pharma, Inc. (the ?Company?), a Delaware corporation, and each stockholder of the Company who is a signatory hereto and each additional person who hereafter becomes a stockholder of the Company and a party to this Agreement in accordance with this |
|
| July 3, 2019 |
EXHIBIT 10.4 License Agreement Amendment This license agreement amendment (?Amendment??) amends the License Agreement dated November 10, 2008 (?Agreement?) by and between RAPTOR THERAPEUTICS INC., having its principal place of business at 9 Commercial Blvd., Suite 200, Novato, CA 94949 (hereinafter referred to as ?Licensor??), formerly known as TorreyPines Therapeutics, Inc.; and QR PHARMA, INC., |
|
| July 3, 2019 |
Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.3 to Form S-1 filed July 3, 2019.) Exhibit 3.3 BY-LAWS OF ANNOVIS BIO, INC. (a Delaware corporation) Adopted on April 29, 2008 BY-LAWS OF ANNOVIS BIO, INC. ARTICLE I OFFICES Section 1.1 Offices. The registered office of the Corporation shall be in the State of Delaware. The Corporation may have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or a |
|
| July 3, 2019 |
EXHIBIT 10.6 License Agreement Amendment Number 2 This license agreement amendment number 2 (?Amendment Number 2?), effective as of May 2, 2012 (?Effective Date?), amends the License Agreement dated November 10, 2008, as amended November 18, 2011 (collectively, the ?Current Agreement?) by and between RAPTOR THERAPEUTICS INC., having its principal place of business at 9 Commercial Blvd., Suite 200, |
|
| July 3, 2019 |
Power of Attorney. (Incorporated by reference to signature page to Form S-1 filed July 3, 2019.) Table of Contents As filed with the Securities and Exchange Commission on July 2, 2019 Registration No. |
|
| July 3, 2019 |
EXHIBIT 10.7 Investigator-Initiated Clinical Trial Agreement This Clinical Trial Agreement (?Agreement?) is made and entered into effective as of the full execution hereof (?Effective Date?), by and between The Regents of the University of California, a California constitutional corporation, on behalf of its San Diego campus, located at 9500 Gilman Drive, La Jolla, CA 92093, California (?Instituti |
|
| July 3, 2019 |
Amended and Restated Certificate of Incorporation of the Registrant, as amended Exhibit 3.1 CERTIFICATE OF INCORPORATION OF QR PHARMA, INC. The undersigned, for the purpose of forming a corporation pursuant to the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: ARTICLE I The name of the corporation is QR Pharma, Inc. (the ?Corporation?). ARTICLE II The address of the Corporation?s registered office in the State |
|
| July 3, 2019 |
EXHIBIT 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT effective as of May 10, 2019 between Annovis Bio, Inc. (the ?Employer?), a Delaware corporation, and Maria L. Maccecchini (the ?Employee?). Recital: The Employer and the Employee are parties to an Amended and Restated Employment Agreement dated as of April 12, 2010 and subsequently amended on January 1, 2011, (collectively |
|
| July 3, 2019 |
EXHIBIT 10.2 Effective Date: April 12, 2018 ANNOVIS BIO, INC. 2018 EQUITY INCENTIVE PLAN The purpose of the Annovis Bio, Inc. (formerly QR Pharma, Inc.) 2018 Equity Incentive Plan (this ?Plan?) is to provide (i) designated employees of Annovis Bio, Inc. (the ?Company?) and its parents and subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its parents or sub |
|
| July 3, 2019 |
EXHIBIT 10.3 LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?), dated as of November 10, 2008, is by and between TORREYPINES THERAPEUTICS, INC., a Delaware corporation having its principal place of business at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA 92037 (hereinafter referred to as ?Licensor?); and QR Pharma, Inc., a Delaware corporation and having its principal place of |
|
| July 2, 2019 |
NEW YORK BALTIMORE LONDON WILMINGTON SINGAPORE MIAMI PHILADELPHIA FIRM and AFFILIATE OFFICES BOCA RATON CHICAGO PITTSBURGH WASHINGTON, DC NEWARK SAN FRANCISCO LAS VEGAS SILICON VALLEY CHERRY HILL SAN DIEGO www. |
